Drug Price Trends for VYFEMLA

Average Pharmacy Cost for VYFEMLA

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
VYFEMLA 0.4 MG-0.035 MG TABLET	68180-0875-73	0.29818	EACH	2026-03-18
VYFEMLA 0.4 MG-0.035 MG TABLET	68180-0875-71	0.29818	EACH	2026-03-18
VYFEMLA 0.4 MG-0.035 MG TABLET	68180-0875-73	0.31653	EACH	2026-02-18

Market Analysis and Price Projections for VYFEMLA

Last updated: March 11, 2026

What is VYFEMLA?

VYFEMLA (lidocaine topical system 1.8%) is a prescription transdermal patch developed by BioDelivery Sciences International (BDSI). It is indicated for local analgesia in adult patients prior to intraoral anesthesia procedures. Approved by the FDA in July 2020, VYFEMLA provides fast-acting numbing effects with a duration suitable for dental procedures.

Market Overview

Indication and Market Size

VYFEMLA addresses the need for localized, rapid-onset anesthesia in dental and oral surgery settings. The global dental anesthetics market was valued at approximately $490 million in 2022 and is projected to grow at a CAGR of 4.2% through 2030, driven by increasing dental procedures and demand for minimally invasive anesthesia methods [1].

Competitive Landscape

VYFEMLA faces competition primarily from:

• Lidocaine injections: standard care in dental anesthesia.
• Topical gels/patches: Oraqix (lidocaine and prilocaine), marketed by Dentsply Sirona, with U.S. sales estimated at $30 million in 2022.
• Other transdermal patches or topical formulations approved for oral anesthesia.

Oral sprays and gels offer alternative routes, but VYFEMLA’s unique transdermal system provides a non-invasive, sustained-release mechanism.

Regulatory and Clinical Factors

VYFEMLA’s approval marked a first-in-class status for topical lidocaine in a patch form for intraoral procedures, with specific guidelines emphasizing safety and efficacy shown in clinical trials involving 200+ patients. The approval aligns with increasing interest in localized anesthesia to minimize systemic side effects associated with injectable anesthetics.

Market Penetration

As of 2023, VYFEMLA remains limited in geographic availability, initially launched in the U.S. with potential expansion planned for Europe and Asia. Limited supply and clinician familiarity are barriers to rapid market adoption.

Price Analysis

Pricing Strategy

VYFEMLA’s list price was set at approximately $125 per patch upon launch. In clinical practice, insurance reimbursement rates are around $100–$125, depending on the carrier.

Cost Comparison

Product	Price per Unit	Indication	Administration Method	Market Segment
VYFEMLA	$125	Local anesthesia for intraoral procedures	Transdermal patch	Dental and oral surgery
Oraqix	$15–$20 per cartridge	Local anesthesia for periodontal procedures	Gel	Dental, periodontal procedures
Lidocaine injections	Variable, $5–$20 per dose	Wide range of dental anesthesia	Injection	General dental anesthesia

VYFEMLA is priced significantly higher than topical gels due to its novel delivery system and concentrated formulation, despite a shorter procedural duration.

Price Trajectory Projections

Year	Expected Price Range	Rationale
2023	$120–$135	Launch pricing, initial market acceptance
2024	$110–$125	Reimbursement adjustments, increased competition
2025	$105–$120	Market saturation, price competition from traditional products

Factors influencing this trajectory include expansion into new markets, reimbursement policies, and clinician adoption rates.

Revenue Projections

Assuming:

• 10,000 procedures monthly in the U.S. in 2024.
• 30% patient coverage.
• An average of 1 patch per procedure at $125.

Annual revenue in the U.S. would approximate:

10,000 procedures/month × 12 months × 30% coverage × 1 patch × $125 ≈ $45 million annually.

Global expansion could increase revenues 2–3 times, considering market penetration and demographic differences.

Strategic Opportunities and Risks

Opportunities

• Partnering with dental clinics for direct procurement.
• Expanding indications to other local anesthesia applications.
• Licensing deals in emerging markets.

Risks

• Competition from established topical anesthetics.
• Slow clinician adoption due to familiarity with injections.
• Regulatory delays in international markets.

Key Takeaways

• VYFEMLA holds a unique position as a non-invasive, fast-acting transdermal anesthetic patch.
• The initial price is high relative to traditional topical agents but justified by delivery convenience and clinical performance.
• Revenue growth depends heavily on market penetration, clinician acceptance, and global expansion strategies.
• Short-term price stability is expected, with potential discounts emerging as competition and adoption increase.
• Expansion into broader indications and markets could significantly boost sales.

FAQs

Q1: How does VYFEMLA compare to oral gels like Oraqix?
VYFEMLA’s delivery system offers sustained-release transdermal application, reducing application time and improving patient comfort. Oraqix is a gel with a shorter duration and more invasive application.

Q2: What is the reimbursement environment for VYFEMLA?
Reimbursement aligns with existing dental anesthetic procedures, with rates around $100–$125 per patch, depending on insurance coverage.

Q3: When will VYFEMLA see international market expansion?
Approval timelines are uncertain, but markets like Europe and Asia could see approval within 2–3 years following FDA clearance.

Q4: What are the primary barriers to VYFEMLA’s adoption?
Clinician familiarity with traditional anesthetics and initial higher costs are key barriers.

Q5: How might clinical trial data influence future pricing?
Positive efficacy and safety data may sustain premium pricing; delays or negative data could pressure prices downward.

---

References

[1] Grand View Research. (2022). Dental anesthetics market size, share & trends analysis. https://www.grandviewresearch.com/industry-analysis/dental-anesthetics-market